Rituximab Therapy of B-Cell Neoplasms

Clinical Lymphoma

Volumn 1, Issue 3, 2000, Pages 186-194

  Petryk, Magdalena ^a   Grossbard, Michael L ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Anti CD20 monoclonal antibody; Chronic lymphocytic leukemia; Follicular non Hodgkin's lymphoma; Waldenstrom's macroglobulinemia

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; RITUXIMAB;

B CELL LYMPHOMA; CLINICAL TRIAL; HUMAN; MULTIMODALITY CANCER THERAPY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; LYMPHOMA, B-CELL;

EID: 0034575137     PISSN: 15269655     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2000.n.015     Document Type: Review

References (53)

1. Pressman D, Korngold L. The in vivo localization of anti-Wagner osteogenic sarcoma antibody. Cancer 1953; 6:619-623.
2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256:495-497.
3. Nadler LM, Stashenko P, Hardy R, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980; 40:3147-3154.
4. Multani PS, Grossbard ML. Monoclonal antibody-based therapies for hematologic malignancies. J Clin Oncol 1998; 16:3691-3710.
5. Maloney D, Smith B, Applebaum F. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct anti-proliferative activity and induction apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood 1996; 88:637a (Abstract #2535).
6. Taji H, Kagami Y, Okada Y, et al. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody. Jpn J Cancer Res 1998; 89:748-756.
7. Pearson M, Shinn C, Grever M, et al. Rituximab induces in vitro apoptosis in human chronic lymphocytic leukemia cells independent of complement mediated lysis but requires Fcg receptor ligation. Blood 1999; 94:313 (Abstract #4626).
8. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose Infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84:2457-2466.
9. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997; 15:3266-3274.
10. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90:2188-2195.
11. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825-2833.
12. Grillo-Lopez AJ, Cheson BD, Horning SJ, et al. Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates. Ann Oncol 2000; 11:399-408.
13. Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17:1851-1857.
14. Piro LD, White CA, Grillo-Lopez AJ, et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10:655-661.
15. Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 2000; 18:3135-3143.
16. Johnson PW, Rohatiner AZ, Whelan JS, et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13:140-147.
17. Igarashi T, Ohtsu T, Fujii, et al. Rituximab re-treatment can produce prolonged failure-free survival for relapsed Indolent B-cell lymphoma. Blood 1999; 94; 262b (Abstract # 4384).
18. Hainsworth JD, Burris HA 3rd, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin's lymphoma. Blood 2000; 93:3052-3056.
19. Solal-Celigny P, Salles G, Brousse N, et al. Rituximab as a first-line treatment of patients with follicular lymphoma and a low-burden tumor: clinical and molecular evaluation. Blood 1999; 94:631a (Abstract #2802).
20. Grillo-Lopez A, Lee D, Alkuzewny B, et al. Clinical activity of rituximab in patients who have relapsed following ABMT. Proc Am Soc Clin Oncol 2000; 19:23a (Abstract #81).
21. Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997; 12:177-186.
22. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17:268-276.
23. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol 1999; 26(suppl 14):88-96.
24. Garcia-Conde J, Conde E, Sierra J, et al. Rituximab (IDEC-C2B8) and CVP chemotherapy in follicular or low grade B-cell lymphoma after relapse: results after 6 months of follow-up. Proc Am Soc Clin Oncol 2000; 19:27a (Abstract #96).
25. Emmanouilides C, Rosen P,Teletar M, et al. Excellent tolerance of rituximab when given after mitoxantrone-cyclophosphamide: an effective and safe combination for indolent NHL. Clin Lymphoma 2000; 1:146-151.
26. Czuczman M, Jonas C, Stephan M, et al. Pilot study of Rituxan in combination with fludarabine chemotherapy in patients with low-grade or follicular non-Hodgkin's lymphoma. Proc Am Soc Clin Oncol 1999; 18:17a (Abstract #61).
27. Davis TA, Maloney DG, Grillo-Lopez AJ, et al. Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. Clin Cancer Res 2000; 6:2644-2652.
28. Sacchi S, Federico M, Vitolo U, et al. Phase II study of rituximab after priming with IFN in patients with relapsed low grade/follicular B-cell lymphoma. Blood 1999; 94:91a (Abstract #399).
29. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317-324.
30. Foran JM, Cunningham D, Coiffier B, et al. Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 2000; 11:117-121.
31. Ghielmini M, Schmitz SF, Burki K, et al. The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 2000; 11:123-126.
32. Howard O, Gribben J, Neuberg D, et al. Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma. Blood 1999; 94:631a (Abstract #2804).
33. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92:1927-1932.
34. Link B, Grossbard M, Fisher R, et al. Phase II pilot study of the safety and efficacy of rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate- or high-grade NHL. Proc Am Soc Clin Oncol 1998; 17:3a (Abstract #7).
35. Gutierrez M, Grossbard M, Little R, et al. Dose-Adjusted Epoch Chemotherapy (CT) and Rituximab (EPOCH-R): an Effective Regimen in Poor Prognosis Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL). Proc Am Soc Clin Oncol 2000; 19:26a (Abstract #95).
36. Tirelli U, Sparano J, Hopkins U, et al. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide (CDE) plus the anti-CD20 monoclonal antibody rituximab in HIV-associated non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 2000; 19:44a (Abstract #170).
37. O'Brien S, Freireich E, Andreeff M, et al. Phase I/II study of rituxan in chronic lymphocytic leukemia (CLL). Blood 1998; 92:105a (Abstract #431).
38. Byrd J, Grever M, Davis B, et al. Phase I/II study of thrice weekly rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma: a feasible and active regimen. Blood 1999; 94:704a (Abstract #3114).
39. Keating M, O'Brien S, Cortes J, et al. Fludarabine and Cyclophosphamide Combined with Rituxan (FCR) Is a Potent Cytoreductive Regimen as Initial Therapy of Chronic Lymphocytic Leukemia. Proc Am Soc Clin Oncol 2000; 19:8a (Abstract #21).
40. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999; 17:791-795.
41. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94:2217-2224.
42. Byrd JC, White CA, Link B, et al. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity. Ann Oncol 1999; 10:1525-1527.
43. Treon S, Agus D, Link B, et al. Rituximab is an active agent in waldenstroms macroglobulinemia (WM). Proc Am Soc Clin Oncol 2000; 19:6a (Abstract #13).
44. Treon SP, Shima Y, Grossbard ML, et al. Treatment of multiple myeloma by antibody mediated immunotherapy and Induction of myeloma selective antigens. Ann Oncol 2000; 11:107-111.
45. Treon SP, Shima Y, Preffer FI, et al. Treatment of plasma cell dyscrasias by antibody-mediated Immunotherapy. Semin Oncol 1999; 26:97-106.
46. Treon S, Shima Y, Preffer F, et al. Interferon-g induces CD20 expression on multiple myeloma patient and healthy donor plasma cells and augments binding of rituximab. Proceeding of the International Conference on Malignant Lymphoma. Ann Oncol 1999; 10:34.
47. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95:1502-1505.
48. Milpied N, Vasseur B, Parquet N, et al, Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11: 113-116.
49. Garrett TJ, Chadburn A, Barr ML, et al. Posttransplantation lymphoproliferative disorders treated with cyclophosphamide-doxorubicin-vincristine-prednisone chemotherapy. Cancer 1993; 72:2782-2785.
50. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330:1185-1191.
51. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92:1549-1555.
52. Fisher A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med 1991; 324:1451-1456.
53. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92:3137-3147.